Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy
Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.
Inclusion Criteria:
Fingolimod patients will constitute the fingolimod cohort while patients with the other DMT will constitute the parallel cohort
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Sottsdale, Arizona 85258, United States
Jenin, Buenos Aires 6000, Argentina
Ciudad Autonoma de Bs As, Argentina
Saint Catharine's, Ontario L2R 2P7, Canada
Culiacan, State of Mexico 80020, Mexico